Efflux in bacteria: What do we really know about it?

Expert Opinion on Investigational Drugs

Volumn 10, Issue 8, 2001, Pages 1409-1422

  Ryan, B M ^a   Dougherty, T J ^a   Beaulieu, D ^a   Chuang, J ^a   Dougherty, B A ^a   Barrett, J F ^a  

^a Bristol Meyers Squibb   (United States)

Author keywords

Antibiotic resistance; Bacteria; Efflux; Genomics; Potentiation

Indexed keywords

ALKALOID; AMIDE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CHEMICAL COMPOUND; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN; DRUG; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MC 02434; MC 02595; MC 04124; MC 510050; MC 510051; NATURAL PRODUCT; NORFLOXACIN; OFLOXACIN; PEPTIDE DERIVATIVE; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; QUINOLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RESERPINE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOCHEMISTRY; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; DRUG ACTIVITY; EXOCYTOSIS; GENE SEQUENCE; IN VITRO STUDY; IN VIVO STUDY; INFORMATION SCIENCE; LABORATORY; MICROBIOLOGY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA; REVIEW;

BACTERIA; BACTERIAL TOXINS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG RESISTANCE;

EID: 0034895316     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.8.1409     Document Type: Review

References (79)

1. The structure and function of drug pumps
2. Multidrug resistance pumps provide broad defense
3. Multidrug resistance: Versatile drug sensors of bacterial cells
4. Structure and function of multidrug transporters
5. Proton-dependent multidrug efflux systems
6. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria
7. The P-glycoprotein efflux pump: How does it transport drugs?
8. Antibiotic efflux pumps
9. ABC transporters: From microorganisms to man
10. Overview, clinical relevance, and potential pharmaceutical target
11. A bacterial model system for understanding multi-drug resistance
12. Antibiotic resistance caused by gram-negative multidrug efflux pumps
13. Multidrug resistance mechanisms: Drug efflux across two membranes
14. Resistance to macrolide mediated by efflux mechanisms
15. The multidrug efflux protein NorM is a prototype of a new family of transporters
16. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance
17. The ostensible paradox of multidrug recognition
18. Regulation of the permeability of the gonococcal cell envelope by the mtr system
19. Comparative biosequence metrics
20. Basic local alignment search tool
21. Improved tools for biological sequence comparison
22. CLUSTAL: A package for performing multiple sequence alignment on a microcomputer
23. Hidden Markov models
24. Comparative genomics of microbial drug efflux systems
25. Status of genome projects for nonpathogenic bacteria and archaea
26. The ecoCyc and MetaCyc databases
27. Enterococcus faecalis multi-drug resistance transporters: Application for antibiotic discovery
28. Natural functions of bacterial multidrug transporters
29. Multidrug resistance efflux
30. Drug efflux proteins in multidrug resistant bacteria
31. Molecular pharmacological characterization of two multidrug transporters in Lactococcus lactis
32. MdfA, an Escherichia coli multidrug resistance protein with an extraordinary broad spectrum of drug recognition
33. A multidrug efflux transporter in Listeria monocytogenes
34. Ins and outs of antimicrobial resistance era of the drug pumps
35. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates
36. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
37. AcrD of Escherichia coli is an aminoglycoside efflux pump
38. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides
39. The SMR family: A novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs
40. A broad-specificity multidrug efflux pump requiring a pair of homologous SMR-type proteins
41. An ABC-type multidrug transporters of Lactococcus lactis possesses an exceptionally broad substrate specificity
42. Characterization of a new staphylococcal gene, VgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds
43. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability
44. Resistance to β-Lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and β-Lactamase
45. Efflux-mediated resistance to fluoroquinolone in gram-positive bacteria and the mycobacteria
46. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci
47. The role of efflux in macrolide resistance
48. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM
49. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae
50. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial Levofloxacin
51. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines
52. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus
53. Deletion of efflux pumps affects the emergence of resistance to Levofloxacin in P. aeruginosa
54. Multidrug resistance pumps as important targets in antibacterial therapy
55. Use of genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa
56. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance
57. Identification and characterization of efflux pump inhibitors in P. aeruginosa
58. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy
59. Efflux pumps inhibitors (EPIs) enhance the activity of antimicrobial agents against a broad selection of bacteria
60. Potentiation of levofloxacin (levo) by a broad-spectrum efflux pump inhibitor (EPI) in mouse models of infection due to Pseudomonas aeruginosa
61. An inhibitor of the Mex pumps from Pseudomonas aeruginosa is also a substrate of these pumps
62. Addressing the stability of c-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa
63. Potentiation of levofloxacin by MC-02,595, a broad spectrum efflux pump inhibitor in mouse models of infection due to Pseudomonas aeruginosa with combinations of different Mex pump expression and gyrA mutation
64. Peptidomimetics of dipeptide amide efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa
65. An efflux pump inhibitor MC-04, 124, enhances the activity of macrolides against gram negative bacteria
66. MF-GA-372 and MF-GA-371 S novel bacterial efflux pump inhibitors from microbial fermentation
67. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein
68. Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: Structure-activity relationship